{"name":"Inhibrx Biosciences, Inc","slug":"inhibrx-biosciences-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQRnotVjN2ODFYZ3Y0THo2WDVEc0l5bUNqLTFYSTJMMVZ4Y0NJQ294NmEweDYzTjAzN1VGOHI4ZTNoUXg0bWlkRGNVSzAxNVZySHdPaV9PR3VKMUdfcDI2dHpkQ2hMM2tRa2JpSmtmSjFKb0VPRkRveWQ3aHg1VTFmbDRHc2o5TGRLeWtZY09HVllCaVlqam1iMUxrVDlha1J6UndHR2JRdktpYnFRNHRv?oc=5","date":"2026-03-19","type":"pipeline","source":"Stock Titan","summary":"[10-K] Inhibrx Biosciences, Inc. Files Annual Report - Stock Titan","headline":"[10-K] Inhibrx Biosciences, Inc. Files Annual Report","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPVUJmdGNOV2pJOUdrVnQ3aUtHWmZZckdmTzg0U2ZOYldSMTBwTEF0ek9CSENDU014Ym1rUmVUaEdIUHlPbDduMC1POUxHcHJscnM4ZUJlcTZuZFFfU0lpR0c4TVRwVjNKUGhSNVFtc0F6N2U4MzUxd080dWkwQ3gtV1hYRUhncjNxZnk5ZVhhRDJWU1ZQMDk2dTc3V3FVazdDWHFsbU9nLUVGZTdNakFQd2I3akxsOTNnbkh3bDJ3?oc=5","date":"2026-03-02","type":"pipeline","source":"PR Newswire","summary":"Inhibrx Announces Participation in Upcoming Scientific Conference - PR Newswire","headline":"Inhibrx Announces Participation in Upcoming Scientific Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxPTk1YUXBQN2tLdWY5RllZY29OTFVCcWNoSXNnOUR0eUhVdTJBYVRRbTNTcXlPYW5kMFl3Q0dGMHlmOXA4SWZvMmV0cXRieWwxNXlEM2NpVU5aYWFMSTQxSFV4OHRMLWlwZk9lblNJeHBuaWlIeW5PWDVXMzBZU3pLeVNERVB2NWlCNHpGQmljN0dMQVg4M2FGeTBpUnl2UjhqcGRmanhqNlV0RDFtQW5wWkJMaHFDQ3FyREVrTkV3aEV6c0ZEVHc5OU9peEliZk9KcC1TNXVJN3VXS1gxaFc3djk4VmgzUV80U1JMR1BKTExMN0dMMGNYVkphMTdQNUNRX0d2TTdDeEw2TkN0cjlyeE8yMmpBUFJhNERiWVRkbw?oc=5","date":"2026-02-26","type":"pipeline","source":"PR Newswire","summary":"Chondrosarcoma Treatment Market Forecasts Robust Growth During the Forecast Period (2026-2036) as Oncology Pipeline Strengthens | DelveInsight - PR Newswire","headline":"Chondrosarcoma Treatment Market Forecasts Robust Growth During the Forecast Period (2026-2036) as Oncology Pipeline Stre","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQbE82UlRsbVJlLU5kQXRRRGRDZ3c3M3hORVg5TWNJQ3ZPZ2VDRUFGUG5uSjRSMU9DZkI0SHFIOGNmNUlXMjMtU3RPX3phcEVGZGNwZVA3dkxGdExoTlFFZ3B3TFlYRUFvR29EN0dwaWpHZDM3cVJzeVItbzBmdkRGczBMTWJVaFZlZkNQck9UMmZyVG02VHBhOERGWkxpY2RVb0xxeElUcVpWZTlVckYwTEROakJxa0JIUU5ySFFyZw?oc=5","date":"2026-01-22","type":"pipeline","source":"Bloomberg.com","summary":"Llamas Are Big Pharma’s Secret Weapon to Find New Drugs - Bloomberg.com","headline":"Llamas Are Big Pharma’s Secret Weapon to Find New Drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxOdEdBM183VGExUXhpdEJyY09OT3locW8zR2haaFJuT04zc3QzM1R1QmxQRVdjUFAxNnNoZ0hnTXQxRXgxSEtEXzY1eml0bHh1YXNSdnpZamJBU3liVzlGT3N3RTdaVXVnZkstdkt5aXh4NG95aDNvdjI4d2JOVFF1WlZSODlLZU9Tc2ZnSmZHdGJSLUdZMGh3S0lvVmw1MnlpYjNHOEdFZWZnY2JHSTdSTlF3QXFGWVhZZjUtY2Q1YU9LN2NRNFlEWG9RM0ViRHp6MnY4TWgxVDZiQzdjMDVwcW5rWk5FYWot0gHuAUFVX3lxTE56MEFMRlFldFVwT2JMOWlWYmF2Uy1DMk9MUUJDcWJrZ0pxeXNhaE1LbEZyU3l0Zk1nMFhPV1g3anBjdnVvR3BLN3Z2azUxSFh6dVltZ2xQVWNMN1dHUXl6QndNOC1YbGlaUVFPQmZFb0lBM3NRUHVzOTFHMGJlc215NGdwdzc4N2NJbml0V0VTQUFPbGRTekFSUmdzVDEyblg3RURyV2IyYV9BN2YyVUlZemFFUkh0d1FkeUNaalVIclpvNFhSLVQ0WU1TVVozeFdBQTFVYmJ3MGUwaUpXUTd3cHNEc3NLWHIta09pT0E?oc=5","date":"2025-12-18","type":"regulatory","source":"simplywall.st","summary":"Inhibrx Biosciences (INBX): Assessing Valuation After New Oncology Pipeline and FDA Milestone Updates - simplywall.st","headline":"Inhibrx Biosciences (INBX): Assessing Valuation After New Oncology Pipeline and FDA Milestone Updates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPaUpyeWJyM0V4YWo0eHBXSW5nYk9TaEpSa0pRVzE5dTFNXzVkazMzNm1mU25QLVVVcnd6cjlCYmRoeXBORjk4MXlkNlc5SXdObFp2ZjJFTVVUeVJiRk9SckFlVExCM3B2cEFfcnlOQ1c1RUNBcTAyVkFRMXNiTlA3VlBfS3M0bE5mRVZTSWRRQ2NSaF85Q3B5RjlXZ1FKYUdtWDZCeEQ1NHlmRV9RM1QyU2lIRDJWbFh3?oc=5","date":"2025-10-27","type":"regulatory","source":"Seeking Alpha","summary":"Inhibrx Biosciences: Cruising Toward FDA Approval, But Getting Ahead Of Itself - Seeking Alpha","headline":"Inhibrx Biosciences: Cruising Toward FDA Approval, But Getting Ahead Of Itself","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOQjhjY3phZ2xSMDVNYXQ1NnVicjNGM3VpRHRCRG1hUFgtaWRyR09XM2RNeG93bHk5NldJOUlXem14NkQxUnEtNm51dm1scWdDcVJxMHp2UzhKTzZ1T0dUZzFYV3RhSmc2ZWV6RU1MdWNmV2EycXhpcFFTNnh4ZHQ1T2s0ckZ2R2hBRlJGT0xvYW5vdGY0MU5Ld214RQ?oc=5","date":"2025-10-24","type":"trial","source":"Clinical Trials Arena","summary":"Inhibrx Biosciences’ stock soars on chondrosarcoma Phase II victory - Clinical Trials Arena","headline":"Inhibrx Biosciences’ stock soars on chondrosarcoma Phase II victory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxORVVqNkxNMk1aVzRZdFdYWGRKeTlSc3RrM1VkWko4a3lpRkU2LWxWSVRVYS05elJJWmhiUG01WExwQWJKN1dOS0Fod1FaR291QnIycnVrMEM1Nll4M2s5emR0TnA4VUI3MEdha01jU0FLWExWR2NrRVNJTU5IT1JzTS1GLU5NbHl1R2I1QjcxZWk5SHY2bUtZVjdzUC1oR0NrY05WeklubEcwTGlhMlNLMVV4WFdBRFE?oc=5","date":"2025-10-24","type":"regulatory","source":"Fierce Biotech","summary":"Inhibrx eyes FDA submission after phase 2 rare bone cancer win - Fierce Biotech","headline":"Inhibrx eyes FDA submission after phase 2 rare bone cancer win","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNZERobjZ0cUgxd3MzRmpsblA2c3QxYTBxMGpTU00tWVF4YXFNdFZyVjQ0RV8weWo5blV3WHRpRW1xVU5VUnVwUTAyRGdDcVpjVVYtaWNDM2R0a01SZjYwN2pIRndxRFA5TGl2RWR6dVpBTXRDWlZ6dEFGYnBMbHkwLTlaUExncXJ3ZGdLbGVOQXZlVEZZV0Q0YkxwdEZGbWM?oc=5","date":"2025-10-24","type":"pipeline","source":"BioWorld News","summary":"Inhibrx’s positive results in rare cancer prompts BLA talk - BioWorld News","headline":"Inhibrx’s positive results in rare cancer prompts BLA talk","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gJBVV95cUxQbVhuN21uR1pKQ1RITnpXcUVQT1NaOXp0OWlMVnRhR2tpeTgzd3JnQ2xCbkdCNURHQ1dBbWRQYjhKYU5TbFRNU0wzcHN1Mjd0TzhtWTI2eXZTMzhYaktsSmtwMWp4Wk00VFZkbkZnMm5tSjNGdnFUcmNjQkZiVkJIclh2N1NUdVg5QXg4QkFqRHJwcGhwN0FDdW8wSG9TYmFBMkh5RkpRLS1yQ05pMTNXc0FCY2NEWXQzSXdGNXVxblFEcUtDaHd0YTRRNXNjblVlOUdsR3RNN3IwcTU2Q2xtd3M4RVBfTUJ4RFREcmxHdTFNZEFJNXdFWVp1R3hNWXJDcW8tSzUyMVB2YVZQUGVibnNYa1VOdTlIRDU4R1B5ZzE2RjdsNTRERnd5ZFlIT2s0eUZpekZROHl0dFcwbE5BLS1tTTZMOTB2MldTUV9RajJ0UGZOSHc?oc=5","date":"2025-10-23","type":"trial","source":"Newswise","summary":"Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Coho","headline":"Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosa","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOckdsakVQYWdTbENjNWtmbmZnOEVwZVAtUmYwMTZwSk5iVHFsNzZKelRscWJKa3BNTFN0OF9KYk93cS1xNVN2dlpYSWFHOXF2RHUydVRZLU4waVpLOWpyaTVnSWlvdlFLNHhkbnA1elJOSUJCTnJscEsxbzVnNnplUW5KVlhIY29SVWo2YURwTTZaSkQtN2pobQ?oc=5","date":"2025-10-22","type":"trial","source":"BioPharma Dive","summary":"Sanofi drug acquired in buyout succeeds in rare disease trial - BioPharma Dive","headline":"Sanofi drug acquired in buyout succeeds in rare disease trial","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-18","type":"pipeline","source":"simplywall.st","summary":"Is Inhibrx Biosciences (NASDAQ:INBX) A Risky Investment? - simplywall.st","headline":"Is Inhibrx Biosciences (NASDAQ:INBX) A Risky Investment?","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}